Convalescent plasma therapy for COVID-19
Department of Pharmaceutics, SJVPM Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research; Chinchwad, Pune-411019, MH- India.
Review Article
World Journal of Advanced Research and Reviews, 2021, 11(03), 192–200
Article DOI: 10.30574/wjarr.2021.11.3.0399
Publication history:
Received on 16 August 2021; revised on 18 September 2021; accepted on 20 September 2021
Abstract:
The outbreak of severe acute respiratory syndrome COVID-19 caused by SARS-CoV-2 in China represents a significant threat to global health. Unfortunately, effective therapeutic drugs and vaccines to cure SARS-CoV-2 are still lacking. Convalescent Plasma therapy which induces passive immunization seems a successful treatment for COVID-19 patients and also proves to be of huge value in terms of saving the severely ill patient. Plasma therapy acts by Blocking the Virus (Neutralization), Enhancing Phagocytosis (Opsonization), Immune System Activation (Complement Activation), and finally killing Virus (Antibody-Dependent Cell-mediated Cytotoxicity). Food and Drug Administration (FDA) of the United States was also given the stamp of approval for use of plasma therapy on 23 August 2020. In this review, we introduced the effective level of antibodies, potential mechanisms of CPT, WHO criteria for donating the plasma as well as future uncertainties of convalescent plasma therapy in the treatment of COVID-19 patients.
Keywords:
Convalescent plasma therapy; COVID-19; Neutralization; Passive immunization; Complement Activation
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0